Post-heparin LPL activity measurement using VLDL as a substrate: a new robust method for routine assessment of plasma triglyceride lipolysis defects

Archive ouverte

Di Filippo, M. | Marcais, C. | Charriere, S. | Marmontel, O. | Broyer, M. | Delay, M. | Merlin, M. | Nollace, A. | Valero, R. | Lagarde, M. | Pruneta-Deloche, V. | Moulin, Philippe | Sassolas, A.

Edité par CCSD ; Public Library of Science -

International audience. BACKGROUND: Determination of lipoprotein lipase (LPL) activity is important for hyperchylomicronemia diagnosis, but remains both unreliable and cumbersome with current methods. Consequently by using human VLDL as substrate we developed a new LPL assay which does not require sonication, radioactive or fluorescent particles. METHODS: Post-heparin plasma was added to the VLDL substrate prepared by ultracentrifugation of heat inactivated normolipidemic human serums, diluted in buffer, pH 8.15. Following incubation at 37 degrees c, the NEFA (non esterified fatty acids) produced were assayed hourly for 4 hours. LPL activity was expressed as micromol/l/min after subtraction of hepatic lipase (HL) activity, obtained following LPL inhibition with NaCl 1.5 mmol/l. Molecular analysis of LPL, GPIHBP1, APOA5, APOC2, APOE genes was available for 62 patients. RESULTS: Our method was reproducible (coefficient of variation (CV): intra-assay 5.6%, inter-assay 7.1%), and tightly correlated with the conventional radiolabelled triolein emulsion method (n = 26, r = 0.88). Normal values were established at 34.8 +/- 12.8 micromol/l/min (mean +/- SD) from 20 control subjects. LPL activities obtained from 71 patients with documented history of major hypertriglyceridemia showed a trimodal distribution. Among the 11 patients with a very low LPL activity (\textless10 micromol/l/min), 5 were homozygous or compound heterozygous for LPL or GPIHBP1 deleterious mutations, 3 were compound heterozygous for APOA5 deleterious mutations and the p.S19W APOA5 susceptibility variant, and 2 were free of any mutations in the usual candidate genes. No homozygous gene alteration in LPL, GPIHBP1 and APOC2 genes was found in any of the patients with LPL activity \textgreater10 micromol/l/min. CONCLUSION: This new reproducible method is a valuable tool for routine diagnosis and reliably identifies LPL activity defects.

Suggestions

Du même auteur

An APOA5 3' UTR variant associated with plasma triglycerides triggers APOA5 downregulation by creating a functional miR-485-5p binding site

Archive ouverte | Caussy, Cyrielle | CCSD

International audience. APOA5 c.*158C\textgreaterT (rs2266788), located in the 3' UTR, belongs to APOA5 haplotype 2 (APOA5*2), which is strongly associated with plasma triglyceride levels and modulates the occurrenc...

New CRISPR Technology for Creating Cell Models of Lipoprotein Assembly and Secretion

Archive ouverte | Anaganti, N. | CCSD

International audience. PURPOSE OF REVIEW: This review is aimed at providing an overview of new developments in gene editing technology, including examples of how this technology has been used to develop cell models...

A TG-associated minor LPL haplotype supresses miR-29 binding on LPL 3'UTR

Archive ouverte | Caussy, C. | CCSD

International audience. Aim: Identification and functional study of Lipoprotein Lipase (LPL) 3'UTR polymorphisms associated with triglyceridemia and predicted to modulate miRNA binding.Methods: We sequenced LPL 3'UT...

Chargement des enrichissements...